Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2015 07:00 ET | Source: Emergent Biosolutions, Inc.

Emergent BioSolutions Receives FDA Approval of Anthrasil, Its Anthrax Immune Globulin, for Use in the Treatment of Inhalational Anthrax

GAITHERSBURG, Md., March 25, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved Anthrasil™ [Anthrax...
March 24, 2015 07:00 ET | Source: Emergent Biosolutions, Inc.

Emergent BioSolutions Awarded $31 Million Contract for Advanced Development of NuThrax, a Next Generation Anthrax Vaccine

GAITHERSBURG, Md., March 24, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract with the Biomedical Advanced Research and Development...
March 16, 2015 07:00 ET | Source: Emergent Biosolutions, Inc.

Emergent BioSolutions Signs Agreements With Oxford University, GlaxoSmithKline, and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate

Emergent has completed proof-of concept manufacturing of an MVA Ebola Zaire vaccine candidate anticipated for use in a Phase 1 clinical study in the UK 200L scale production leverages...
March 09, 2015 07:00 ET | Source: Emergent Biosolutions, Inc.

Emergent BioSolutions and MorphoSys Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate Cancer

GAITHERSBURG, Md. and MARTINSRIED/MUNICH, Germany, March 9, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) today...
March 05, 2015 16:01 ET | Source: Emergent Biosolutions, Inc.

Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2014 Financial Results and Provides Update on 2015 Outlook

GAITHERSBURG, Md., March 5, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and twelve months ended December 31, 2014. Financial highlights...
February 20, 2015 07:00 ET | Source: Emergent Biosolutions, Inc.

Emergent BioSolutions to Participate in March 2015 Investor Conferences

GAITHERSBURG, Md., Feb. 20, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company's senior management team will participate in the following...
February 13, 2015 07:00 ET | Source: Emergent Biosolutions, Inc.

Emergent BioSolutions Announces Primary Endpoints Met in Pivotal Study Supporting Licensure of Building 55

GAITHERSBURG, Md., Feb. 13, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced completion of the in-life phase of the pivotal nonclinical efficacy study designed to...
February 12, 2015 07:00 ET | Source: Emergent Biosolutions, Inc.

Emergent BioSolutions to Release Fourth Quarter and Full Year 2014 Financial Results and Conduct a Conference Call on March 5, 2015

GAITHERSBURG, Md., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, March 5, 2015 at 5:00 pm (Eastern Time) to discuss the financial...
January 11, 2015 15:00 ET | Source: Emergent Biosolutions, Inc.

Emergent BioSolutions Announces Preliminary 2014 Financial Results and Provides 2015 Financial Outlook

2014 Preliminary Estimates: Total revenues of $445 to $450 million, a 43% increase over 2013 (at midpoint) GAAP net income of $36 to $38 million, a 19% increase over 2013 (at...
January 07, 2015 07:00 ET | Source: Emergent Biosolutions, Inc.

Emergent BioSolutions to Participate in January 2015 Investor Conferences

ROCKVILLE, Md., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company's senior management team will participate in the following investor...